New drug combo aims to outsmart pancreatic cancer before surgery

NCT ID NCT06203821

Not yet recruiting Disease control Sponsor: Aram Hezel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial will test whether adding the study drug NP137 to standard chemotherapy (FOLFIRINOX) can change the behavior of pancreatic cancer cells before and after surgery. About 25 people with resectable pancreatic cancer will receive the combination, and researchers will look for signs that the tumor becomes less aggressive. The goal is to see if this approach is safe and might help prevent the cancer from coming back or spreading.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NP137 (a study drug) plus FOLFIRINOX chemotherapy
What this could lead to: If it works, this could point toward a new treatment approach for pancreatic cancer that may help control the disease and reduce the chance of it spreading.
What could go wrong: This is a very early Phase 1 trial with only 25 people, so it is primarily testing safety and feasibility. The drug may not work as hoped, and side effects from the combination could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.